{
    "clinical_study": {
        "@rank": "77114", 
        "arm_group": {
            "arm_group_label": "Treatment (decitabine, MEC)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive decitabine IV over 60 minutes on days -9 to -5 (dose level 1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3).\nINDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV over 30 minutes on days 1-5, etoposide IV over 1 hour on days 1-5, and cytarabine IV over 1 hour on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy."
        }, 
        "brief_summary": {
            "textblock": "This phase I/II trial studies the side effects and best dose of decitabine followed by\n      mitoxantrone hydrochloride, etoposide, and cytarabine and to see how well it works in\n      treating patients with relapsed or refractory acute myeloid leukemia or high-risk\n      myelodysplastic syndromes. Drugs used in chemotherapy, such as mitoxantrone hydrochloride,\n      etoposide, cytarabine, and decitabine, work in different ways to stop the growth of cancer\n      cells, either by killing the cells or by stopping them from dividing. Giving more than one\n      drug (combination chemotherapy) may kill more cancer cells."
        }, 
        "brief_title": "Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes", 
        "condition": [
            "Adult Acute Basophilic Leukemia", 
            "Adult Acute Eosinophilic Leukemia", 
            "Adult Acute Megakaryoblastic Leukemia (M7)", 
            "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", 
            "Adult Acute Monoblastic Leukemia (M5a)", 
            "Adult Acute Monocytic Leukemia (M5b)", 
            "Adult Acute Myeloblastic Leukemia With Maturation (M2)", 
            "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", 
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Adult Acute Myelomonocytic Leukemia (M4)", 
            "Adult Erythroleukemia (M6a)", 
            "Adult Pure Erythroid Leukemia (M6b)", 
            "Previously Treated Myelodysplastic Syndromes", 
            "Recurrent Adult Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Basophilic, Acute", 
                "Leukemia, Eosinophilic, Acute", 
                "Leukemia, Erythroblastic, Acute", 
                "Leukemia, Megakaryoblastic, Acute", 
                "Leukemia, Monocytic, Acute", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelomonocytic, Acute", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Hypereosinophilic Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Estimate the maximum tolerated dose (MTD) of decitabine priming followed by sequential\n      mitoxantrone hydrochloride/etoposide/cytarabine (MEC) chemotherapy in adults with\n      relapsed/refractory acute myeloid leukemia (AML).\n\n      SECONDARY OBJECTIVES:\n\n      I. Determine, within the limits of a Phase 1/2 study, disease response and duration of\n      remission.\n\n      II. Identify biomarkers (e.g., deoxyribonucleic acid [DNA] methylation and/or gene\n      expression changes) associated with treatment responses.\n\n      OUTLINE: This is a phase I, dose-escalation study of decitabine followed by a phase II\n      study.\n\n      Patients receive decitabine intravenously (IV) over 60 minutes on days -9 to -5 (dose level\n      1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3).\n\n      INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV over 30 minutes on days\n      1-5, etoposide IV over 1 hour on days 1-5, and cytarabine IV over 1 hour on days 1-5.\n      Patients achieving complete response (CR) or CR with incomplete platelet count recovery\n      (CRp) may receive up to 2 courses of induction therapy and up to 2 courses of consolidation\n      therapy.\n\n      After completion of study treatment, patients are followed up every 3 months for up to 5\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Prior diagnosis of \"high-risk\" myelodysplastic syndrome (MDS) (>= 10% blasts) or AML\n             other than acute promyelocytic leukemia (APL) with t(15;17) (q22;q12) or variants\n             according to the 2008 World Health Organization (WHO) classification; patients with\n             biphenotypic AML are eligible\n\n          -  Relapsed/persistent disease according to standard criteria requiring salvage therapy;\n             outside diagnostic material is acceptable as long as peripheral blood and/or bone\n             marrow slides are reviewed at the study institution; flow cytometric analysis of\n             peripheral blood and/or bone marrow should be performed according to institutional\n             practice guidelines\n\n          -  Patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT)\n             are eligible if relapse occurs > 180 days post-transplant provided symptoms of\n             graft-versus host disease are well controlled with stable use of immunosuppressive\n             agents\n\n          -  Treatment-related mortality (TRM) score =< 9.2 as calculated with simplified model\n\n          -  Should be off any active therapy for AML with the exception of hydroxyurea for at\n             least 14 days prior to study registration unless patient has rapidly progressive\n             disease, and all grade 2-4 non-hematologic toxicities should have resolved\n\n          -  May have previously received monotherapy with demethylating agents for MDS or AML\n\n          -  May have previously received chemotherapy with MEC for MDS or AML\n\n          -  Patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) >\n             100,000/uL can be treated with leukapheresis or may receive up to 2 doses of\n             cytarabine (up to 500 mg/m^2/dose) prior to enrollment\n\n          -  Bilirubin =< 2 x institutional upper limit of normal (IULN) unless elevation is\n             thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis\n             (assessed within 7 days prior to registration)\n\n          -  Serum creatinine =< 1.5 x IULN (assessed within 7 days prior to registration)\n\n          -  Left ventricular ejection fraction >= 40%, assessed within 3 months prior to\n             registration, e.g. by multi gated acquisition (MUGA) scan or echocardiography, or\n             other appropriate diagnostic modality and no clinical evidence of congestive heart\n             failure; if the patient had anthracycline-based therapy since the most recent cardiac\n             assessment, cardiac evaluation should be repeated if there is clinical or\n             radiographical suspicion of cardiac dysfunction, or if the previous cardiac\n             assessment was abnormal\n\n          -  Women of childbearing potential and men must agree to use adequate contraception\n\n          -  Provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Refractory/relapsing myeloid blast crisis of chronic myeloid leukemia (CML), unless\n             patient is not considered candidate for tyrosine kinase inhibitor treatment\n\n          -  Concomitant illness associated with a likely survival of < 1 year\n\n          -  Active systemic fungal, bacterial, viral, or other infection, unless disease is under\n             treatment with anti-microbials and/or controlled or stable (e.g. if specific,\n             effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis,\n             human immunodeficiency virus {HIV}]); patient needs to be clinically stable as\n             defined as being afebrile and hemodynamically stable for 24-48 hours\n\n          -  Known hypersensitivity to any study drug\n\n          -  Pregnancy or lactation\n\n          -  Patients may not be receiving any other investigational agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01729845", 
            "org_study_id": "2652.00", 
            "secondary_id": [
                "NCI-2012-02224", 
                "2652.00", 
                "P30CA015704"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (decitabine, MEC)", 
                "description": "Given IV", 
                "intervention_name": "decitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-aza-dCyd", 
                    "5AZA", 
                    "DAC"
                ]
            }, 
            {
                "arm_group_label": "Treatment (decitabine, MEC)", 
                "description": "Given IV", 
                "intervention_name": "mitoxantrone hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CL 232315", 
                    "DHAD", 
                    "DHAQ", 
                    "Novantrone"
                ]
            }, 
            {
                "arm_group_label": "Treatment (decitabine, MEC)", 
                "description": "Given IV", 
                "intervention_name": "etoposide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "EPEG", 
                    "VP-16", 
                    "VP-16-213"
                ]
            }, 
            {
                "arm_group_label": "Treatment (decitabine, MEC)", 
                "description": "Given IV", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARA-C", 
                    "arabinofuranosylcytosine", 
                    "arabinosylcytosine", 
                    "Cytosar-U", 
                    "cytosine arabinoside"
                ]
            }, 
            {
                "arm_group_label": "Treatment (decitabine, MEC)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Decitabine", 
                "Etoposide phosphate", 
                "Etoposide", 
                "Mitoxantrone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 4, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Arunbhai G. Patel", 
                    "phone": "509-783-0144"
                }, 
                "facility": {
                    "address": {
                        "city": "Kennewick", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99336"
                    }, 
                    "name": "Columbia Basin Hematology and Oncology PLLC"
                }, 
                "investigator": {
                    "last_name": "Arunbhai G. Patel", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roland B. Walter", 
                    "phone": "206-667-3599"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
                }, 
                "investigator": {
                    "last_name": "Roland B. Walter", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center", 
            "last_name": "Roland Walter", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "MTD of decitabine defined as the highest dose in which the incidence of dose limiting toxicity (DLT) is < 33%, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 45"
            }, 
            {
                "description": "Categorized according to criteria recommended by International Working Groups.", 
                "measure": "Remission rate (RR) including CR and CRp (Phase II)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01729845"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Categorized according to criteria recommended by International Working Groups.", 
                "measure": "Event-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Categorized according to criteria recommended by International Working Groups.", 
                "measure": "Disease-free survival (for patients achieving CR or CRp)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Categorized according to criteria recommended by International Working Groups.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}